InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, is reporting additional preclinical data demonstrating the positive effects of its INM-901 for the potential treatment of Alzheimer’s disease (“AD”). Highlights of the report note that INM-901 receptor binding studies indicate preferential signaling agonism for both cannabinoid 1 (“CB1”) and cannabinoid 2 (“CB2”) and impacts the peroxisome proliferator-activated receptors (“PPAR”) signaling pathway while in vivo studies demonstrate INM-901 reduces neuroinflammation and improves neuronal function. In addition, molecular analysis data explains previously reported observations in behavioral studies on locomotion, memory and cognition. According to the announcement, several preclinical studies were conducted in well-characterized AD models and the company plans to accelerate the development of its AD program. “The recent results demonstrating pharmacological effects in in vivo disease models continue to validate INM-901 as a potential treatment of AD,” said InMed senior vice president of preclinical research and development Dr. Eric Hsu in the press release. “We are particularly encouraged with indications that INM-901 has multiple potential mechanisms of action as a preferential signaling agonist for both cannabinoid 1 and cannabinoid 2 receptors, as well as impacting the peroxisome proliferator-activated receptor signaling pathway. There continues to be a major unmet medical need for this multi-factorial disease and differentiated therapeutic mechanisms may play an important role. We believe the development of INM-901 may address several pathological factors including neuroinflammation, neuroprotection and neuritogenesis.”
To view the full press release, visit https://www.cnw.fm/3wpHd
About InMed Pharmaceuticals Inc.
InMed Pharmaceuticals is a global leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs. Together with its subsidiary, BayMedica, the company has unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. InMed is a clinical-stage company developing a pipeline of rare cannabinoid therapeutics with programs in Alzheimer’s disease, age-related macular degeneration, glaucoma and epidermolysis bullosa. For more information, please visit www.InMedPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.cannabisnewswire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW? Ask our Editor
CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CannabisNewsWire is part of the InvestorBrandNetwork.
